<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895921</url>
  </required_header>
  <id_info>
    <org_study_id>R21MH082805</org_study_id>
    <secondary_id>R21MH082805</secondary_id>
    <secondary_id>DATR A5-ETSE</secondary_id>
    <secondary_id>071224</secondary_id>
    <nct_id>NCT00895921</nct_id>
  </id_info>
  <brief_title>Examining the Effects of Antipsychotic Medications on Insulin Sensitivity</brief_title>
  <official_title>Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of two different antipsychotic medications on control of&#xD;
      blood sugar in people who are at risk of diabetes but mentally healthy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antipsychotic medications are those that treat the most severe psychiatric symptoms, such as&#xD;
      hallucinations, paranoid thoughts, and delusions. Research shows that some of these&#xD;
      medications may put people at a higher risk of metabolic derangements, such as insulin&#xD;
      resistance. Certain antipsychotics, like clozapine and olanzapine, are associated with a&#xD;
      higher risk of metabolic side effects than others, like aripiprazole and ziprasidone. Because&#xD;
      people with schizophrenia may experience adverse side effects from switching antipsychotic&#xD;
      medications and because it is difficult to find people with schizophrenia who do not have&#xD;
      experience taking antipsychotics, this study will use people without psychiatric disorders&#xD;
      who are at risk for diabetes in place of people with schizophrenia. The study will compare&#xD;
      the effects of single doses of two antipsychotic medications, olanzapine and aripiprazole, on&#xD;
      insulin action in this population. In addition to determining metabolic effects of these&#xD;
      medications, this study will also seek to demonstrate the feasibility of using mentally&#xD;
      healthy people at risk of diabetes as a substitute for people with schizophrenia in studying&#xD;
      these effects.&#xD;
&#xD;
      Participation in this study will last 4 weeks. Participants will first complete a screening&#xD;
      visit that will include the following: an oral glucose tolerance test (OGTT), which involves&#xD;
      a blood draw, consumption of a sugar drink, and then a second blood draw; a review of medical&#xD;
      and psychiatric history, including use of medicines and psychiatric medications; and&#xD;
      measurement of participants' height and weight. The second visit, scheduled 2 weeks after&#xD;
      screening, will include a tracer-clamp study to test how participants' bodies handle sugar.&#xD;
      The tracer-clamp study will be conducted over the course of one night and morning and will&#xD;
      require participants to stay at the study location overnight. At 3 AM, participants will&#xD;
      receive an intravenous line (IV) with a sugar solution. Just before 8 AM, they will receive a&#xD;
      second IV in the opposite arm that will draw blood and monitor blood sugar levels.&#xD;
&#xD;
      At 8 AM, participants will begin receiving insulin in the first IV; blood samples will be&#xD;
      drawn and blood sugar levels will be monitored during this time to ensure they remain within&#xD;
      a healthy range. At 11 AM, participants will receive an injection of an antipsychotic&#xD;
      medication into their arm muscles. The antipsychotic, which will be randomly assigned, will&#xD;
      be either olanzapine or aripiprazole. Participants will be monitored for 3 hours after&#xD;
      receiving the injection of antipsychotic medication; during this time, more blood samples&#xD;
      will be drawn, blood sugar levels will be monitored to ensure they are within a healthy&#xD;
      range, and secondary medications will be available to counteract certain side effects of the&#xD;
      antipsychotics. After 2 more weeks, participants will undergo a third study visit in which&#xD;
      they repeat the OGTT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glucose Disposition</measure>
    <time_frame>Measured over 6 hours</time_frame>
    <description>Ratio of post-antipsychotic/pre-antipsychotic glucose disposition as measured using the hyperglycemic clamp technique. This method allows one to measure either how well an individual metabolizes glucose or how sensitive an individual is to insulin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent of Insulin Suppression of Endogenous Glucose Production</measure>
    <time_frame>Measured over 6 hours</time_frame>
    <description>Ratio of Post-Antipsychotic/Pre-Antipsychotic Percent of Insulin Suppression of Endogenous Glucose Production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Akathisia</measure>
    <time_frame>6 hours</time_frame>
    <description>Number of subjects reporting mild or greater complaints of akathisia after antipsychotic administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive an injection of olanzapine during the tracer-clamp study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Single intramuscular 10-mg dose</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Single intramuscular 9.75-mg dose</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prediabetic, defined as 2-hour post-load serum glucose between 140 and 199 mg/dl on a&#xD;
             75-gram standard oral glucose tolerance test (OGTT) within the past 90 days&#xD;
&#xD;
          -  Family history of type 2 diabetes mellitus&#xD;
&#xD;
          -  Body mass index (BMI) between 25 and 35 kg/m2&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
          -  Nonsmoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Axis I mood, anxiety, or psychotic disorder, confirmed by Structured&#xD;
             Clinical Interview for DSM-IV&#xD;
&#xD;
          -  Use of psychotropic drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan M. Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD and Veterans Affairs San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <results_first_submitted>November 25, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Jonathan M. Meyer, MD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Insulin Resistance</keyword>
  <keyword>Antipsychotic Medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Participants will receive an injection of aripiprazole during the trace-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine</title>
          <description>Participants will receive an injection of olanzapine during the trace-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Male subjects ages 40-65 with impaired glucose tolerance as measured by oral glucose tolerance testing.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine</title>
          <description>Participants will receive an injection of olanzapine during the tracer-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="5.57"/>
                    <measurement group_id="B2" value="54.4" spread="5.97"/>
                    <measurement group_id="B3" value="51.17" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose Disposition</title>
          <description>Glucose disposition is measured using the hyperglycemic clamp technique. This method allows one to measure either how well an individual metabolizes glucose or how sensitive an individual is to insulin.</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.88" spread="1.99"/>
                    <measurement group_id="B2" value="3.31" spread="1.35"/>
                    <measurement group_id="B3" value="3.60" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Suppression of Endogenous Glucose Production (EGP)</title>
          <units>% suppression of EGP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.28" spread="20.30"/>
                    <measurement group_id="B2" value="86.52" spread="22.34"/>
                    <measurement group_id="B3" value="85.40" spread="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose Disposition</title>
        <description>Ratio of post-antipsychotic/pre-antipsychotic glucose disposition as measured using the hyperglycemic clamp technique. This method allows one to measure either how well an individual metabolizes glucose or how sensitive an individual is to insulin.</description>
        <time_frame>Measured over 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Participants will receive an injection of olanzapine during the tracer-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Disposition</title>
          <description>Ratio of post-antipsychotic/pre-antipsychotic glucose disposition as measured using the hyperglycemic clamp technique. This method allows one to measure either how well an individual metabolizes glucose or how sensitive an individual is to insulin.</description>
          <units>ratio of post/pre values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread=".324"/>
                    <measurement group_id="O2" value="1.42" spread=".300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>The a priori threshold for statistical significance is &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.00943</ci_lower_limit>
            <ci_upper_limit>.47605</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent of Insulin Suppression of Endogenous Glucose Production</title>
        <description>Ratio of Post-Antipsychotic/Pre-Antipsychotic Percent of Insulin Suppression of Endogenous Glucose Production</description>
        <time_frame>Measured over 6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Participants will receive an injection of olanzapine during the tracer-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent of Insulin Suppression of Endogenous Glucose Production</title>
          <description>Ratio of Post-Antipsychotic/Pre-Antipsychotic Percent of Insulin Suppression of Endogenous Glucose Production</description>
          <units>ratio of post/pre values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0594" spread=".519"/>
                    <measurement group_id="O2" value="1.312" spread=".642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.269</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt; 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.253</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.224</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.208</ci_lower_limit>
            <ci_upper_limit>0.714</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Akathisia</title>
        <description>Number of subjects reporting mild or greater complaints of akathisia after antipsychotic administration</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>Participants will receive an injection of olanzapine during the tracer-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Akathisia</title>
          <description>Number of subjects reporting mild or greater complaints of akathisia after antipsychotic administration</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of akathisia rates between the two arms.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.400</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.149</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.095</ci_lower_limit>
            <ci_upper_limit>.705</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Participants will receive an injection of aripiprazole during the tracer-clamp study.&#xD;
Aripiprazole: Single intramuscular 9.75-mg dose</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine</title>
          <description>Participants will receive an injection of olanzapine during the tracer-clamp study.&#xD;
Olanzapine: Single intramuscular 10-mg dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <description>Akathisia: mild or greater severity by subjective complaints</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan M. Meyer, MD</name_or_title>
      <organization>Veterans Medical Research Foundation</organization>
      <phone>858-964-0777</phone>
      <email>jmmeyer@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

